Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins.
Kierzek AM, Hickling TP, Figueroa I, Kalvass JC, Nijsen M, Mohan K, Veldman GM, Yamada A, Sayama H, Yokoo S, Gulati A, Dhanikula RS, Gokemeijer J, Leil TA, Thalhauser CJ, Giorgi M, Swat MJ, Chelliah V, Small BG, Benson N, Walker M, Gadkar K, Quarmby V, Deng R, Ferrante A, Dickinson GL, Van Der Walt JS, Zhou L, Chen X, Jones HM, Narula J, Tourdot S, Lavé T, Ribba B, van der Graaf PH. Kierzek AM, et al. Among authors: quarmby v. CPT Pharmacometrics Syst Pharmacol. 2019 Nov;8(11):773-776. doi: 10.1002/psp4.12465. Epub 2019 Oct 8. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 31529677 Free PMC article. No abstract available.
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1).
Wu B, Sternheim N, Agarwal P, Suchomel J, Vadhavkar S, Bruno R, Ballinger M, Bernaards CA, Chan P, Ruppel J, Jin J, Girish S, Joshi A, Quarmby V. Wu B, et al. Among authors: quarmby v. Clin Transl Sci. 2022 Jan;15(1):130-140. doi: 10.1111/cts.13127. Epub 2021 Aug 25. Clin Transl Sci. 2022. PMID: 34432389 Free PMC article.
The quintessence of immunogenicity reporting for biotherapeutics.
Shankar G, Arkin S, Devanarayan V, Kromminga A, Quarmby V, Richards S, Subramanyam M, Swanson S. Shankar G, et al. Among authors: quarmby v. Nat Biotechnol. 2015 Apr;33(4):334-6. doi: 10.1038/nbt.3181. Nat Biotechnol. 2015. PMID: 25850051 No abstract available.
Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2).
Peters S, Galle PR, Bernaards CA, Ballinger M, Bruno R, Quarmby V, Ruppel J, Vilimovskij A, Wu B, Sternheim N, Reck M. Peters S, et al. Among authors: quarmby v. Clin Transl Sci. 2022 Jan;15(1):141-157. doi: 10.1111/cts.13149. Epub 2021 Sep 28. Clin Transl Sci. 2022. PMID: 34582105 Free PMC article.
Real-world data prognostic model of overall survival in patients with advanced NSCLC receiving anti-PD-1/PD-L1 immune checkpoint inhibitors as second-line monotherapy.
Julian C, Machado RJM, Girish S, Chanu P, Heinzmann D, Harbron C, Gershon A, Pfeiffer SM, Zou W, Quarmby V, Zhang Q, Chen Y. Julian C, et al. Among authors: quarmby v. Cancer Rep (Hoboken). 2022 Oct;5(10):e1578. doi: 10.1002/cnr2.1578. Epub 2022 Jan 24. Cancer Rep (Hoboken). 2022. PMID: 35075804 Free PMC article.
65 results